Form S-1
We note your disclosure that you are "the third largest for-profit national provider" in the Individual market. Please disclose your basis for this statement. Additionally clarify if you mean you are the third largest in a specific state, in all 15 states where you operate or otherwise.
No reply letter found.
We note that Health insurance subsidiary adjusted administrative expenses of $257.1 million is the basis for your InsuranceCo Administrative expense ratio calculation in 2019 which is reconciled to selling, general and administrative expenses of health insurance subsidiaries of $224.9 million, a non-GAAP measure. Please revise your disclosure to reconcile to the most directly comparable GAAP measure.Rest of the question
Refer to Item 10(e)(1)(i)(B).
No reply letter found.
Tell us why it is appropriate to remove your premium deficiency reserves from your InsuranceCo Administrative Expense Ratio as disclosed in sub-note (a) to footnote (6). In this regard, it appears to be a normal, recurring, cash operating expense. See Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.Rest of the question
In your response also tell us your consideration for including this reserve in your Medical Loss Ratio as it represents future claims to be incurred.
No reply letter found.
You disclose depreciation and amortization separately from your selling, general and administrative expenses in your statement of operations and comprehensive loss. Please tell us why you do not appear to allocate any depreciation and/or amortization to your Medical Loss Ration, InsuranceCo Administrative Expense Ratio and resulting InsuranceCo Combined Ratio when presumably at least some of the underlying assetsRest of the question
are used in the claims processing and administrative function.
No reply letter found.
We note you disclose Adjusted EBITDA of $129.5 million for your health insurance subsidiaries and $92.7 million for Holdco and its non-health insurance subsidiaries in footnote (c) of your Adjusted EBITDA reconciliation to the most directly comparable GAAP financial performance measure. These each appear to be non-GAAP measures.Rest of the question
Please provide a reconciliation of each to reflect how these allocations reconcile to respective GAAP measures. Refer to Item 10(e)(1)(i)(B) of Regulation S-K.
No reply letter found.
Please explain what your relationship is with Oscar Medical Group. If it is a related party or affiliate, please disclose, and explain in what manner it is so. Additionally, in the Business section disclose the material terms of your management agreements with Oscar Medical Group. File these agreements as exhibits to your registration statement, or tell us why this is not required.
No reply letter found.
Please state the approximate amount intended to be used for each purpose listed in the first sentence of the second paragraph, or tell us why you are unable to do so.
No reply letter found.
Please disclose membership for the periods presented by market, product and plan and discuss material period over period changes.
No reply letter found.
Please disclose the number of partnerships with other payers and providers in which cobranded insurance is powered by your platform for the periods presented and discuss significant period over period changes.
No reply letter found.
Please disclose new and retained membership for the periods presented and discuss
No reply letter found.
We note that incurred but not reported claims are generally more heavily weighted to the "most recent months" as characterized in the second and third paragraphs on page 77. Given that "completion factors are the most significant factors [you] use in developing [your] benefits payable estimates for periods prior to the most recent months," and that it appears that trend factors are more significant to the estimateRest of the question
for the most recent months, please: • Revise your disclosure to place a more definitive time frame on the "most recent months," for example, whether this is two, three or more months; and • Tell us your consideration for providing separate benefits payable sensitivity information for reasonably likely changes in trend factors.
No reply letter found.
You disclose that your technology saves Oscar and members money by routing care to high value providers. Please enhance your disclosure to describe how you define a high value provider.
No reply letter found.
Please disclose how you determined and calculated that the care routing feature in Oscar resulted in estimate median member savings of approximately 6% for the nine months ended September 30, 2020 for members who accepted the top recommendation. Our Network, page 96
No reply letter found.
Please disclose the nine largest health systems in the U.S. that are part of your network. Reinsurance, page 100
No reply letter found.
We note your disclosure on page 78 that you have reinsurance agreements with two reinsurers. Please disclose the percentage of coverage ceded to each reinsurer, the nature and amount of collateral in trust under the contracts and any related party information, if applicable. In addition, please file these agreements as exhibits to the registration statement or advise why you are not required to do so.
No reply letter found.
We note that you have filed employment offer letters for Mr. Schlosser, Mr. Klein and Ms. Joyce as Exhibits 10.11, 10.12 and 10.13. Please describe the material terms of these employment agreements. Refer to Item 402(o)(1) of Regulation S-K.
No reply letter found.
Please revise footnotes (1), (2) and (4) to the table on page 128 to disclose the relationship between you and the respective related party entity.
No reply letter found.
We note that your forum selection provision identifies a state court located within the State of Delaware as the exclusive forum for certain litigation, including any “derivative action” and that the federal district courts are the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.Rest of the question
Please state that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. In that regard, we note that Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.
No reply letter found.
You disclose that you charge any PDR to selling, general and administrative expenses. Please tell us why you do not charge any PDR to claims incurred expense when a premium deficiency essentially represents future expected claims in excess of future premiums to be earned on existing policies.Rest of the question
Reference for us any authoritative literature you rely upon to support your accounting/classification and tell us what journal entries you make in a hypothetical future period assuming the anticipated premium deficiency indeed comes to fruition.
No reply letter found.
Please disclose your statutory net income or loss for 2019. See Rule 7-03(a)23(c) of Regulation S-X.
No reply letter found.
It is apparent that your benefits reserve rollforward on page F-23 does not include claims adjustment expenses (CAE) as required by ASC 944-40-50-3. Please address the following and reference for us, where appropriate, the authoritative literature you rely upon to support your accounting and/or disclosure: • Revise your disclosure to include CAE in this rollforward or tell us why it is not required and/or why yourRest of the question
presentation is appropriate; • Revise your accounting and disclosure to include CAE with the associated claims expense as required by Rule 7-04.5 of Regulation S-X or tell us why it is not required; and • Confirm for us that none of your CAE is allocated to your claims incurred and paid presented in your claims development table presented on page F-22 or revise those tables as required by ASC 944-40-50-4B.
No reply letter found.
Please tell us why the reinsurance recoverable of $76.2 million in the reconciliation of total benefits payable at December 31, 2019 on page F-23 differs significantly from the $516.1 million presented on your balance sheet.Rest of the question
To the extent that the difference relates to reinsurance recoverable on paid losses, given that the reconciliation under ASC 944-4050-4C requires disclosure of reinsurance recoverable on unpaid claims, tell us: • Why such a significant amount of ceded claims in 2019 have yet to be collected from reinsurers given the claims payments made and short tail associated with health insurance claims; and • How any delayed payment or collection terms qualify your reinsurance contracts for reinsurance accounting under ASC 944-20-15-40, with specific emphasis on subparagraph b.
No reply letter found.
Please file your material contracts as exhibits to the registration statement and describe their material terms or advise why you are not required to do so. In this regard, we note your references to the following partnerships or agreements in the prospectus: • affiliations with Tenet Healthcare and AdventHealth on pages 31; • partnership with Cleveland Clinic on page 62, 85, and 97; • partnership with Cigna onRest of the question
pages 85 and 86; • partnerships with Montefiore, Holy Cross and Memorial Health on pages 85-86; • prescription benefits management provided by CareMarkPCS Health on page 33; • Tenth Amended and Restated Investors' Rights Agreement on page 128; • Tenth Amended and Restated First Refusal and Co-Sale Agreement on page 129; and • various technology service agreements with affiliates of Alphabet Holdings LLC on page 129.
No reply letter found.
Please provide us with supplemental copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, have presented or expect to present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not you retained, or intend to retain, copies of those communications. Please contact Tonya K.Rest of the question
Aldave at (202) 551-3601 to discuss how to submit the materials, if any, to us for our review.
No reply letter found.
We note that throughout the prospectus you often describe the industry and your performance using compound annual growth rate ("CAGR"). Please balance your disclosure by also discussing that such growth trends may not continue.
No reply letter found.
We note your response to our prior comment 1 and reissue in part. Please disclose the basis for your statement that you are "the third largest for-profit national insurer in the Individual market in the United States based on membership."
No reply letter found.
We note that you present Adjusted InsuranceCo EBITDA. Please revise your disclosure to reconcile to the most directly comparable GAAP measure, consistent with Consolidated Adjusted EBITDA. Refer to Item 10(c)(1)(i)(B) of Regulation S-K.
No reply letter found.
You disclose that Adjusted EBITDA helps you measure your core operating performance over time by removing items that are not related to day-to-day operations. You also state that Adjusted InsuranceCo EBITDA represents your revenue and expenses for your core products.Rest of the question
Considering that you only have one operating segment, please revise your disclosures to more distinctly address how you define "core" operating performance as measured by Adjusted EBITDA versus Adjusted InsuranceCo EBITDA revenue and expenses from your "core" products.
No reply letter found.
We note your response prior comment 8. Considering you signed up 14,000 members in New York eight years ago which you highlight in your Letter from Co-Founders, please enhance your discussion on page 66 to discuss the factors that can impact member retention to address the decrease in membership in New Jersey, New York and Ohio from 2019 to 2020.
No reply letter found.
We note your response to prior comment 21. Please address the following: • As previously requested, Revise your accounting and related disclosures to include CAE with your claims incurred, net on the face of your statement of operations as required by Rule 7-04.5 of Regulation S-X.Rest of the question
• Revise your accounting and related disclosures to include your liability for CAE with your benefits payable on your balance sheet as required by Rule 7-03(a)13(a) of Regulation S-X. • To the extent that you believe the guidance referenced in the preceding bullets is not required, tell us why in your response and reference for us the authoritative literature you rely upon to support your accounting.
No reply letter found.
We note your response to prior comment 22 and that $516.1 million of reinsurance recoverables were collected in the first quarter of 2020 and that such amounts related to quarters three and four of 2019. We also note on page F-18, that you disclose reinsurance losses ceded for the entire year ended December 31, 2019 were $516.1 million. Please explain this discrepancy and revise your disclosures accordingly.
No reply letter found.
We acknowledge your response to prior comment 6. Please revise your presentation to include only amounts due from reinsurers for paid and unpaid claims and claim adjustment expenses in your reinsurance recoverable asset consistent with the guidance in ASC 944-310-25-2 and the definition of reinsurance recoverables in ASC 944-20-20.Rest of the question
In addition, tell us whether you have any prepaid reinsurance premiums and report them separately as required by ASC 944-340-25-1. Alternatively, revise the caption on the face of your balance sheet and provide disclosure of the components in your footnotes.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages F-4, F-7 and F-21. The Company does not have any prepaid reinsurance premiums that are required to be reported separately as assets under ASC 944-340-25-1.Read in the reply
* * *
We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (212) 906-1761 with any questions or comments regarding this correspondence.
We note that your pro forma and pro forma as adjusted disclosures contemplate transactions where some shareholders appear to gain rights while others lose rights. In this regard, we note: • from page 13 and elsewhere that:o Thrive Capital will effectively gain 19 votes per share on its preferred stock which was previously convertible into Series A common stock with one vote per share that will now effectivelyRest of the question
convert into Class B common stock with 20 votes per share; o the Co-Founders will similarly gain 19 votes per share on all preferred stock and exiting Series A common stock as they too will receive Class B common stock with 20 votes per share instead of Series A common stock at one vote per share; o the Co-Founders will effectively gain 10 votes per share on all Series B common stock which previously had 10 votes per shares when they receive Class B common stock with 20 votes per share; and o Series B common stockholders, other than the Co-Founders, will effectively lose nine votes per share when their 10-vote per share Series B common stock is converted into one-vote per share Class A common stock; and • from page 147 that Mario Schlosser will have options exercisable for 20-vote per share Class B common stock that apparently were previously exercisable for one-vote per share Series A common stock. Please tell us how you plan to account for these apparent changes in rights and how you will reflect them in your pro forma and pro forma as adjusted presentation. Reference for us the authoritative literature you rely upon to support your anticipated accounting.
The Company respectfully acknowledges the Staff’s comment and advises the Staff that, consistent with the treatment ofRead in the reply
Series B common stock in the pre-initial public offering certificate of incorporation (the “Pre-IPO Charter”), the certificate of incorporation to be in effect on or around consummation of the initial public offering (the “IPO Charter”) provides that, subject to certain exceptions for permitted holders, the Class B common stock automatically converts to Class A common stock upon a transfer of shares of Class B common stock, including upon a sale.Rest of the answer
Because the holders of Class B common stock cannot convey their super voting rights upon a transfer of such stock, subject to certain exceptions for permitted holders, the value of such stock is equivalent to the value of the Class A common stock. Similarly, in the Pre-IPO Charter, subject to certain exceptions for permitted holders, the Series B common stock with 10 votes per share automatically converts to Series A common stock with 1 vote per share upon a transfer. The shares should not materially increase in economic value due to the change in voting rights from the transition from the Pre-IPO Charter to the IPO Charter because (i) all high vote shares convert to shares with 1 vote per share upon a transfer and in any event, the high voting rights granted in the IPO charter terminate 7 years from the date of the initial public offering, (ii) Thrive Capital had material voting control prior to the offering and will continue to have such control after the offering and (iii) relative to Thrive Capital, Mario Schlosser’s voting power does not materially change his ability to exercise control within the Company. Therefore, the Company believes the change in voting rights will not impact the Company’s pro forma and pro forma as adjusted presentation. To the extent that there were material value to these changes, the Company would follow ASC 718 consistent with other equity modification arrangements.
From the warrant liability rollforward on page F-24 and the disclosure regarding your Series A11 preferred stock call options on pages F-29 and II-3, it appears that the fair value of these options was about $1.09 per share at issuance in May and June 2020 and about $1.00 per share at exercise in November and December 2020.Rest of the question
During this time, we note that your Series A11 preferred stock was issued at $6.01898 per share in May and June 2020 and that your Series A12 preferred stock was issued for $9.69438 per share in December 2020. Please tell us why the value of your Series A11 preferred stock call options declined from May/June 2020 to November/December 2020 when it appears that the underlying preferred stock appreciated considerably during this time. In your response, specifically tell us: • whether there are any significant differences in the preferences underlying your Series A11 and Series A12 preferred stock; • the date when the issuance of Series A12 preferred stock was first contemplated; • the date when pricing negotiations in the Series A12 preferred stock issuance began; • who lead the pricing negotiations for the Series A12 investors and any previous relationship to you; • the preliminary issuance price of the Series A12 stock when negotiations began; • the date when the Series A12 issuance was agreed; and • the date(s) when the Series A12 call options were exercised.
, specifically tell us:Read in the reply
whether there are any significant differences in the preferences underlying your Series A11 and Series A12 preferred stock;
the date when the issuance of Series A12 preferred stock was first contemplated;
the date when pricing negotiations in the Series A12 preferred stock issuance began;
who lead the pricing negotiations for the Series A12 investors and any previous relationship to you;
the preliminary issuance price of the Series A12 stock when negotiations began;
the date when the Series A12 issuance was agreed; and the date(s) when the Series A12 call optionsRest of the answer
were exercised.
Response: The Company respectfully acknowledges the Staff’s comment and advises the Staff of the following:
with respect to whether there are any significant differences in the preferences underlying the Company’s series A11 preferred stock and series A12 preferred stock, the series A11 preferred stock has a liquidation preference of $6.02 per share, which is the original issue price, and the series A12 has a liquidation preference of $9.69 per share, which is the original issue price;
the issuance of series A12 preferred stock was first contemplated on November 23, 2020;
the date when pricing negotiations in the series A12 preferred stock began was November 27, 2020;
funds affiliated with Tiger Global Management, LLC led the series A12 preferred stock financing and they had no previous relationship to the Company;
the preliminary issuance price of the series A12 preferred stock when negotiations for that financing began was
$9.69 per share;
the series A12 preferred stock issuance closed on December 17, 2020 and the series A11 preferred stock issuance closed on June 26, 2020; and the series A11 preferred stock call options, as there were no series A12 preferred stock call options, were exercised between November 24, 2020 and December 21, 2020.
The Company further respectfully advises the
Staff, as described in the bulleted responses above, that the series A11 preferred stock instruments and the series A12 preferred stock instruments have different rights and preferences resulting in different values, specifically the significant difference in liquidation preference of $6.02 for the series A11 preferred stock and $9.69 for series A12 preferred stock. The Company’s third-party valuation report, issued by independent valuation experts and applicable during the period of the option exercises, was completed on December 5, 2020, with an effective date of November 30, 2020. This valuation report reflected the expectation that Oscar would issue series A12 preferred stock on the same terms that it ultimately did issue such stock. Using an option pricing method, the report imputed a value of $7.02 per share for the series A11 preferred stock, which was less than the value imputed to the series A12 preferred stock.
The series A11 preferred stock call options were issued at a strike price of $6.02 per share at the time of issuance, which was equal to the fair market value of the series A11 preferred stock. The Company used a Black Scholes model to value these call options, which included key inputs of term, risk free rate, volatility and strike price. As a result, the fair market value of the call option was $1.09 per option. Because the options were issued “at the money,” the non-intrinsic inputs significantly impacted the value of the call options at issuance and included an expected term ending on March 1, 2021.
Given the short term nature of the remaining expected term at exercise, the non-intrinsic value of the call options were immaterial and the Company used the exercise value in determining cumulative warrant expense which resulted in the fair value of $1.00. The specific calculation was derived from the value of the series A11 preferred stock (determined to be $7.02 per share) less the exercise cost (which was $6.02 per share).
We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (212) 906-1761 with any questions or comments regarding this correspondence.
We note the statement that you "have in the past, and we may in the future, fail to take actions mandated by federal and/or state laws or regulations...." Please disclose any material past or current failures. In addition describe to us any ongoing failures. Capitalization , page 69
The Company respectfully acknowledges the Staff’s comment and advises the Staff that we are not aware of any material past or ongoing failures to comply with state laws or regulations. The Company revised its risk factor disclosure after discovering that it had unintentionally failed to notify approximately 2% of its calendar year 2020 members regarding changes in their health plan coverage.Read in the replyRest of the answer
The Company is in the process of remediating this matter, but does not believe the remediation or cost associated with it is material and accordingly does not believe this matter requires additional disclosure in the
Registration Statement.
You disclose in footnote 4 and elsewhere in your filing that the proposed reverse stock split will be effected on or prior to the closing of your offering. Please confirm that although it may be effected prior to closing, it will not be effected prior to effectiveness of your registration statement.Rest of the question
Otherwise, revise the financial statements in your filing to retroactively present the split consistent with the guidance in SAB 4C, have your auditors dual date their report for the impact of the split, and revise your information outside the financial statements to reflect all information on a post-split basis.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page iii to indicate that the Stock Split will be effectuated after the effectiveness of the Registration Statement and prior to closing of the offering.Read in the reply
Please revise the "pro forma as adjusted" description of your Class B Common stock to appropriately reflect the 82,500,000 shares authorized as reflected on page 178 and in the "pro forma" description and to characterize the 35,115,807 shares as being issued and outstanding.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 69.Read in the reply
Please revise your disclosure to consistently present the repayment of your existing Term Loan Facility. In this regard, we note the following apparent inconsistencies: • The narrative description of transactions above the table identifies the Use of Proceeds as a "pro forma as adjusted" transaction yet the carrying value of your Term Loan Facility is not included in your pro forma column as if it is being repaid asRest of the question
a "pro forma" transaction. • Although the liability for your Term Loan Facility is removed from your pro forma column and accumulated deficit has increased $11,847,000 (presumably for the aftertax impact of debt extinguishment), your cash and cash equivalents amount does not appear to reflect the $163 million anticipated repayment amount disclosed in footnote 2. • The $1,765.3 million amount of cash and cash equivalents reflected in your pro forma as adjusted column appears to reflect only the receipt of $936.3 million in net offering proceeds and $2.7 million for stock option exercises and does not appear to reflect the repayment of your Term Loan Facility.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 69 and 70. With respect to the second bullet point, the Company advises the Staff that the estimated fair value of the Warrants and Call Options that have been or will be exercised is $26.9 million (based on the midpoint of the price range set forth on the cover page of the prospectus) of which a liability of $15.1 million has been recorded as of December 31, 2020.Read in the replyRest of the answer
The incremental change in the estimated fair value at the time of exercise has been reflected as an increase in accumulated pro forma deficit of $11.8 million.
In footnote 1 to the table, you indicate that a $1.00 increase in the offering price will result in a $30.4 million increase in net proceeds. Given the number of shares proposed in your offering, this amount appears to be the gross proceeds.Rest of the question
Please revise the amount here and throughout your filing to present your anticipated proceeds net of underwriting discounts and commissions for this hypothetical price increase or tell us why this amount is appropriate.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 70.Read in the reply
Assuming that your reverse stock split will be effected after the effectiveness of your registration statement, please revise your disclosure to also present your historical loss per share information on a post-split basis for the periods presented so that investors in your offering will readily see the historical loss per share that will be presented in future Exchange Act filings under the guidance in SAB TopicRest of the question
4C. This comment also applies to your disclosure in Summary Consolidated Financial and Other Data on page 16.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 17 and 75.Read in the reply
* * *
We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (212) 906-1761 with any questions or comments regarding this correspondence.